메뉴 건너뛰기




Volumn 5, Issue 2, 2011, Pages 165-166

On the updated ECCO consensus guidelines for medical management of Crohn's disease

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

EID: 79953090089     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2010.02.002     Document Type: Letter
Times cited : (10)

References (15)
  • 1
    • 0034754477 scopus 로고    scopus 로고
    • Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial
    • Sandborn W.J., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088-1094.
    • (2001) Gastroenterology , vol.121 , pp. 1088-1094
    • Sandborn, W.J.1
  • 2
    • 4644325814 scopus 로고    scopus 로고
    • CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial
    • Sandborn W.J., et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 2004, 53:1485-1493.
    • (2004) Gut , vol.53 , pp. 1485-1493
    • Sandborn, W.J.1
  • 3
    • 66849137185 scopus 로고    scopus 로고
    • European Medicines Agency, Accessed 12 July 2008
    • Refusal assessment report for Cimzia 2008, European Medicines Agency, Accessed 12 July 2008.
    • (2008) Refusal assessment report for Cimzia
  • 6
    • 70449596780 scopus 로고    scopus 로고
    • SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy
    • abstract
    • Colombel J.F., et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. JCC-J Crohn's Col 2009, 3:S45-S46. abstract.
    • (2009) JCC-J Crohn's Col , vol.3
    • Colombel, J.F.1
  • 7
    • 39449085441 scopus 로고    scopus 로고
    • Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
    • D'Haens G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
    • (2008) Lancet , vol.371 , pp. 660-667
    • D'Haens, G.1
  • 8
    • 32944461717 scopus 로고    scopus 로고
    • Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
    • Rutgeerts P., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006, 63:433-442.
    • (2006) Gastrointest Endosc , vol.63 , pp. 433-442
    • Rutgeerts, P.1
  • 9
    • 70350172248 scopus 로고    scopus 로고
    • Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease
    • Schnitzler F., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15:1295-1301.
    • (2009) Inflamm Bowel Dis , vol.15 , pp. 1295-1301
    • Schnitzler, F.1
  • 10
    • 75049083870 scopus 로고    scopus 로고
    • Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the MUSIC clinical trial
    • Hébuterne X., et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the MUSIC clinical trial. Gut 2008, 57(Suppl II):A15.
    • (2008) Gut , vol.57 , Issue.SUPPL 2
    • Hébuterne, X.1
  • 11
    • 70350684087 scopus 로고    scopus 로고
    • Adalimumab Induces and Maintains Mucosal Healing in Patients with Moderate to Severe Ileocolonic Crohn's Disease - First Results of the Extend Trial
    • abstract
    • Rutgeerts P., et al. Adalimumab Induces and Maintains Mucosal Healing in Patients with Moderate to Severe Ileocolonic Crohn's Disease - First Results of the Extend Trial. Gastroenterology 2009, 136(Suppl 1):751e. abstract.
    • (2009) Gastroenterology , vol.136 , Issue.SUPPL 1
    • Rutgeerts, P.1
  • 12
    • 34547503869 scopus 로고    scopus 로고
    • Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort
    • Frøslie K.F., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
    • (2007) Gastroenterology , vol.133 , pp. 412-422
    • Frøslie, K.F.1
  • 13
    • 75449106111 scopus 로고    scopus 로고
    • Mucosal Healing Predicts Sustained Clinical Remission in Patients with Early-Stage Crohn's Disease
    • Electronic publication ahead of print
    • Baert F., et al. Mucosal Healing Predicts Sustained Clinical Remission in Patients with Early-Stage Crohn's Disease. Gastroenterology Oct. 7 2009, Electronic publication ahead of print.
    • (2009) Gastroenterology
    • Baert, F.1
  • 14
    • 0033529049 scopus 로고    scopus 로고
    • Infliximab for the treatment of fistulas in patients with Crohn's disease
    • Present D.H., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
    • (1999) N Engl J Med , vol.340 , pp. 1398-1405
    • Present, D.H.1
  • 15
    • 10744221312 scopus 로고    scopus 로고
    • Infliximab maintenance therapy for fistulizing Crohn's disease
    • Sands B.E., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
    • (2004) N Engl J Med , vol.350 , pp. 876-885
    • Sands, B.E.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.